🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

213 results for “Bristol” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb / Pfizer EEIG

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  3. -, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  4. 5% Dextrose injection; Solution for injection/infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., 0.9% Sodium Chloride injection; Solution for injection/infusion

    Bristol-Myers Squibb / Pfizer EEIG

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  5. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 other active

    1 trial

  6. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  7. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  8. Amlitelimab, Amlitelimab, -, -, -, Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  9. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  10. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  11. BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers Squibb / Pfizer EEIG

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  13. CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  14. CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  16. CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

    Bristol-Myers Squibb / Pfizer EEIG

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  17. Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

    Sanofi Pharma Bristol-Myers Squibb

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  18. Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

    Sanofi Pharma Bristol-Myers Squibb

    Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  19. Deucravacitinib placebo 3 mg film-coated tablets oral use, Deucravacitinib placebo 6 mg film-coated tablets oral use, deucravacitinib, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Sjogren's syndrome

    phase 3 small molecule active

    1 trial

  20. Dupilumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  21. Dupilumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  22. Duvakitug, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  23. Duvakitug, matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  24. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources